Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Amgen registers Phase 2/3 inebilizumab trial in autoimmune hepatitisOct 16Weekly roundup, 3 itemsAmgenetanerceptUpdated
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trialOct 2Weekly roundup, 5 itemsAmgenapremilastUpdated
Sign inSign in